Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 8/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 8/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30492897 | 0.97 | AKR1C3 (0.43) | AKR1C3AKR1C2MMECES2CES1 | |
| SCHEMBL961088 | 0.97 | AKR1C3 (0.43) | AKR1C3AKR1C2MMECES2CES1 | |
| SCHEMBL909183 | 0.84 | CES2 (0.39) | AKR1C3AKR1C2CES2CES1MEN1 | |
| SCHEMBL961183 | 0.82 | POLB (0.41) | MMEKMT2APOLB | |
| SCHEMBL10277034 | 0.82 | AKR1C3 (0.47) | AKR1C3AKR1C2MMEPOLB | |
| SCHEMBL6122922 | 0.81 | AKR1C3 (0.39) | AKR1C3AKR1C2 | |
| SCHEMBL961452 | 0.81 | CES2 (0.39) | AKR1C3AKR1C2CES2CES1APP | |
| SCHEMBL1533351 | 0.80 | POLB (0.54) | MEN1KMT2APOLB | |
| SCHEMBL909022 | 0.80 | CPN1 (0.44) | CES2CES1MEN1KMT2A | |
| SCHEMBL12500450 | 0.80 | CES2 (0.40) | AKR1C3AKR1C2MMECES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536710-B1 | PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-8486967-B2 | Heteroaryl substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| CN-103025724-A | Piperidine derivatives | HOFFMANN LA ROCHE | 2013-04-03 | — | — | CN | disclosed |
| EP-2536710-A2 | PIPERIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-20120142672-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2455380-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011101304-A2 | PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | HOFFMANN-LA ROCHE, INC. | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142672-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BACE1, APP, BACE2 | AKR1C3 1493/4885AKR1C2 1697/4885MME 51/4885 |
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | APP, HPGDS, PSEN1 | AKR1C3 1860/4885AKR1C2 2654/4885MME 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.